We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
iView Therapeutics Inc. today announced that the first patient has been dosed in the Phase 2 IVIEW-1201-01-AIC clinical trial program assessing the efficacy of IVIEW-1201 in patients (age ≥15 years) with Acute Adenoviral Conjunctivitis. First subject was